MNPR Stock Analysis: Monopar Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 637m USD | 12M Return: 156% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.6M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 6.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Monopar Therapeutics (NASDAQ: MNPR) is a U.S.-based, clinical-stage biopharmaceutical company founded in 2014 and headquartered in Wilmette, Illinois. Its pipeline focuses primarily on oncology and rare disease, anchored by three core programs: ALXN1840, a late-stage oral once-daily investigational therapy in-licensed from Alexion for Wilson disease; MNPR-101, a proprietary humanized monoclonal antibody targeting urokinase plasminogen activator receptor (uPAR) expressed on advanced solid tumors; and two radiopharmaceutical conjugates built off MNPR-101, namely MNPR-101-Zr (a zirconium-89 imaging agent in Phase 1) and MNPR-101-Lu (an actinium-225 radiotherapeutic in Phase 1a). The company also has a collaboration with NorthStar to develop radio-immuno-therapeutics for severe COVID-19 and works with Excel Diagnostics and Nuclear Oncology Center on its imaging and therapeutic candidates.
As a small-cap clinical-stage biotech, Monopar has no marketed products and relies on development milestones, licensing arrangements (such as its Alexion agreement for ALXN1840), and capital markets to fund operations. The radiopharmaceutical and targeted-radiotherapy subsector has become an increasingly active area of oncology investment, with platforms using radioisotope-conjugated antibodies to deliver localized radiation to tumors expressing specific antigens, an approach that aligns with Monopars MNPR-101-based imaging and therapeutic candidates.
- ALXN1840 Phase 3 Wilson disease trial data readout approaches
- MNPR-101 radiopharmaceutical pipeline advances in solid tumor trials
- Cash runway tightens as clinical-stage biotech burns capital without product revenue
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.07 > 0.02 and ΔFCF/TA 11.65 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.07 > 3% & CFO -10.0m > Net Income -15.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 56.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (8.54m) vs 12m ago 22.16% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.98 (Total Current Assets 137.7m - Total Current Liabilities 2.46m) / Total Assets 138.0m |
| B: -0.68 (Retained Earnings -93.4m / Total Assets 138.0m) |
| C: -0.19 (EBIT TTM -18.7m / Avg Total Assets 96.5m) |
| D: 52.29 (Book Value of Equity 135.4m / Total Liabilities 2.59m) |
| Altman-Z'' = 57.83 = AAA |
As of July 08, 2026, the stock is trading at USD 95.22 with a total of 163,557 shares traded. Over the past week, the price has changed by +0.70%, over one month by +57.10%, over three months by +77.62% and over the past year by +155.97%.
Current recommended Stop Loss: 83.30 (which is 12.5% or 2.1 ATR below the current price).
Monopar Therapeutics has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy MNPR.
- StrongBuy: 2
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 113.6 | 19.3% |
P/B = 4.6984
Revenue TTM = 0.0 USD
EBIT TTM = -18.7m USD
EBITDA TTM = -18.7m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 132k USD (from shortLongTermDebtTotal, last quarter) (leases 132k already included)
Net Debt = -137.4m USD (calculated: Debt 132k - CCE 137.5m)
Enterprise Value = 499.3m USD (636.6m + Debt 132k - CCE 137.5m)
Interest Coverage Ratio = unknown (Ebit TTM -18.7m / Interest Expense TTM 0.0)
EV/FCF = -49.87x (Enterprise Value 499.3m / FCF TTM -10.0m)
FCF Yield = -2.01% (FCF TTM -10.0m / Enterprise Value 499.3m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 3.62 (Enterprise Value 499.3m / Total Assets 138.0m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 132k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -14.8m (EBIT -18.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 56.04 (Total Current Assets 137.7m / Total Current Liabilities 2.46m)
Debt / Equity = 0.00 (Debt 132k / totalStockholderEquity, last quarter 135.4m)
Debt / EBITDA = 7.34 (negative EBITDA) (Net Debt -137.4m / EBITDA -18.7m)
Debt / FCF = 13.72 (negative FCF - burning cash) (Net Debt -137.4m / FCF TTM -10.0m)
Total Stockholder Equity = 116.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.52% (Net Income -15.0m / Total Assets 138.0m)
RoE = -12.84% (Net Income TTM -15.0m / Total Stockholder Equity 116.7m)
RoCE = -13.80% (EBIT -18.7m / Capital Employed (Total Assets 138.0m - Current Liab 2.46m))
RoIC = -10.91% (negative operating profit) (NOPAT -14.8m / Invested Capital 135.5m)
WACC = 10.97% (E(636.6m)/V(636.7m) * Re(10.97%) + D(132k)/V(636.7m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -53.94 | Cagr: -21.95%
[DCF] Fair Price = unknown (Cash Flow -10.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.53 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.65 | Chg30d=+0.98% | Revisions=+50% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.77 | Chg30d=+0.83% | Revisions=+50% | Analysts=11
EPS current Year (2026-12-31): EPS=-2.90 | Chg30d=+0.71% | Revisions=+55% | GrowthEPS=-57.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-3.14 | Chg30d=+2.49% | Revisions=+55% | GrowthEPS=-8.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +67% (up=26, down=4)